CSBR
Champions Oncology, Inc.6.73
-1.14-14.5%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
93.45MP/E (TTM)
39.59Basic EPS (TTM)
0.17Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Annual meeting approves board, auditors
Champions Oncology's stockholders unanimously ratified EisnerAmper LLP as independent auditors for fiscal year 2026 at the October 16, 2025 annual meeting. All seven director nominees secured election with strong support, though David Sidransky faced notable withheld votes. The advisory vote on executive compensation passed overwhelmingly. Board continuity bolsters steady governance amid oncology research demands.
8-K
Q1 revenue steady at $14M
Champions Oncology kicked off fiscal 2026 with $14.0 million in revenue, down slightly from $14.1 million last year due to a 3% dip in services offset by data licensing gains, while costs climbed 14.1% to $14.5 million, yielding an operating loss of $527,000 and adjusted EBITDA of $60,000. Gross margins slipped to 43% from 50%, hit by outsourced lab expenses, but in-house shifts promise relief. New CEO Rob Brainin steps in. Steady cash flow builds on $10.3 million reserves, no debt.
10-Q
Q1 FY2026 results
Champions Oncology's oncology revenue dipped 0.5% year-over-year to $14.0M for Q1 FY2026 ended July 31, 2025, yet bookings conversion lifted pharmacology services 1.2% to $13.2M while TOS licenses kicked off at $311K and other TOS fell 54.2% to $454K from de-emphasized flow cytometry. Gross margin slipped to 42.9% from 49.7% as costs climbed 13.1% to $8.0M, driven by outsourced radiolabeling, pushing operating loss to $527K versus $1.3M income last year; net loss hit $466K, with the gap to operating tied to minor other income and taxes. R&D surged 43.2% to $2.1M on data platform and Corellia investments, while sales and marketing rose 10.5% to $1.9M supporting licenses. Cash climbed to $10.3M with $600K operating inflow, free cash flow at $554K (derived), and $182K finance leases maturing through 2028 at low rates; negative working capital persists but liquidity covers needs through October 2026. No M&A or non-GAAP metrics disclosed in the 10-Q. Economic volatility shadows demand from pharma clients.
IPO
Employees
Sector
Industry
BZYR
Burzynski Research Institute, I
0.03-0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CRDF
Cardiff Oncology, Inc.
2.40-0.01
CTOR
Citius Oncology, Inc.
1.07+0.02
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
LADX
LadRx Corporation
0.11+0.00
NTHI
NeOnc Technologies Holdings, In
9.44-0.44
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00